PMID- 25596682
OWN - NLM
STAT- MEDLINE
DCOM- 20150430
LR  - 20161125
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 42
IP  - 1
DP  - 2015 Jan
TI  - [Everolimus plus exemestane in postmenopausal patients with 
      estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of 
      BOLERO -2].
PG  - 67-75
AB  - In a phase 3, double-blind, randomized, international study (the BOLERO-2), the 
      addition of mTOR inhibitor everolimus to exemestane was evaluated in 
      postmenopausal women with estrogen-receptor-positive (ER(+)) advanced/recurrent 
      breast cancer that was refractory to any nonsteroidal aromatase inhibitor (NSAI). 
      This report presents the safety and updated (18- month) efficacy results from the 
      Japanese subset (n=106) of BOLERO-2. After a median follow-up of 18 months, the 
      median progression-free survival time was 8.5 months with everolimus plus 
      exemestane compared to 4.2 months with placebo plus exemestane. The most common 
      adverse events (AEs) with everolimus plus exemestane were stomatitis, rash, 
      dysgeusia, and non-infectious lung disease. The AEs reported with the combination 
      therapy were mostly of grade 1 or 2 and manageable with appropriate intervention. 
      In conclusion, this combination could be a useful addition to the armamentarium 
      of treatments for Japanese postmenopausal women with ER(+) advanced/recurrent 
      breast cancer progressing on NSAIs.
FAU - Ito, Yoshinori
AU  - Ito Y
AD  - Breast Medical Oncology, Breast Oncology Center, Cancer Institute Hospital of 
      JFCR.
FAU - Masuda, Norikazu
AU  - Masuda N
FAU - Iwata, Hiroji
AU  - Iwata H
FAU - Mukai, Hirofumi
AU  - Mukai H
FAU - Horiguchi, Jun
AU  - Horiguchi J
FAU - Tokuda, Yutaka
AU  - Tokuda Y
FAU - Kuroi, Katsumasa
AU  - Kuroi K
FAU - Mori, Asuka
AU  - Mori A
FAU - Ohno, Nobutsugu
AU  - Ohno N
FAU - Noguchi, Shinzaburo
AU  - Noguchi S
LA  - jpn
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Androstadienes)
RN  - 0 (Receptors, Estrogen)
RN  - 9HW64Q8G6G (Everolimus)
RN  - NY22HMQ4BX (exemestane)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Androstadienes/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Double-Blind Method
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Postmenopause
MH  - Receptors, Estrogen/metabolism
MH  - Sirolimus/administration & dosage/analogs & derivatives
EDAT- 2015/01/19 06:00
MHDA- 2015/05/01 06:00
CRDT- 2015/01/19 06:00
PHST- 2015/01/19 06:00 [entrez]
PHST- 2015/01/19 06:00 [pubmed]
PHST- 2015/05/01 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2015 Jan;42(1):67-75.